Background: We observed improved survival among COVID-19 patients receiving remdesivir (RDV) during the early parts of the pandemic (Aug-Nov 2020) [1]. Clinical management of COVID-19 continues to develop over time as variants of concern (VOC) evolve. We extend the previous study to characterize outcomes for patients admitted on low-flow oxygen (LFO) and compare hospital all-cause […]

Case Presentation: A 50-year-old female with rheumatoid arthritis who received 6-monthly maintenance Rituxan infusions, developed COVID-19 and was hospitalized with acute hypoxic respiratory failure. She was treated with 5 days of Remdesivir and discharged with 3L supplemental oxygen to complete a 10-day course of Dexamethasone. She didn’t improve to baseline and was re-hospitalized with progressively […]